Asahi Kasei buys antiviral firm Aicuris for €780m Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

Japanese drugmaker #AsahiKasei has agreed to buy German biotech #Aicuris and its #antiviraltherapy to tackle an infection that can afflict people who undergo a #bonemarrowtransplant.

pharmaphorum.com/news/asahi-k...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients - Aicuris Aicuris has enrolled the final participant in their Phase 3 clinical trial of pritelivir. The study aimed to demonstrate superior efficacy and safety of priteli

Great news from Aicuris! We look forward to seeing their next steps! #Aicuris #Herpes #CureHSV #SilentNoMore

www.aicuris.com/press-releas...